Justdapa-Trio 10/100/500 Tablet ER is a fixed-dose combination oral antidiabetic medication containing Dapagliflozin 10 mg, Metformin 500 mg, and Sitagliptin 100 mg. This extended-release formulation is indicated for the management of type 2 diabetes mellitus in adults to improve glycemic control when diet and exercise alone are insufficient. Dapagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, promotes renal glucose excretion, thereby lowering plasma glucose levels. Metformin, a biguanide, primarily reduces hepatic glucose production and improves insulin sensitivity, enhancing peripheral glucose uptake. Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, increases incretin levels, which inhibit glucagon release and increase insulin secretion in a glucose-dependent manner. The combination targets multiple pathophysiological defects in type 2 diabetes, offering complementary mechanisms to optimize glycemic control. Justdapa-Trio 10/100/500 Tablet ER should be used with caution in patients with renal impairment, hepatic dysfunction, or a history of lactic acidosis. Common adverse effects may include gastrointestinal disturbances, urinary tract infections, and hypoglycemia, particularly when used concomitantly with insulin or insulin secretagogues. Regular monitoring of renal function, glycemic parameters, and patient tolerance is recommended to ensure safe and effective therapy.